THE AMERICAN JOURNAL OF CARDIOLOGY. Angiographic Results of the First Human Experience With the Biolimus A9 Drug-Eluting Stent for De Novo Coronary Lesions

This report describes angiographic findings of the first-in-human evaluation of the Biolimus A9 drug-eluting stent (Biolimus stent) in the treatment of noncomplex coronary lesions. In total, 120 patients with 122 de novo coronary lesions (2.75- to 4.00-mm vessels, ≤24-mm lesion length) were prospectively randomized in a 2:1 ratio to receive the Biolimus stent (n = 80, 82 lesions) or the control uncoated stent (n = 40). Baseline lesion and angiographic characteristics were similar between groups. At 6-month follow-up, late lumen loss was significantly decreased with the Biolimus stent in the stent (0.26 ± 0.43 vs 0.74 ± 0.45 mm, p <0.001) and in the segment (0.14 ± 0.45 vs 0.40 ± 0.41 mm, p = 0.004). In-stent restenosis was 3.9% in the Biolimus stent group versus 7.7% in the control group (p = 0.40). There was no exaggerated hyperplasia at the proximal and/or distal edge of the stent.

STROKE. Neuroimaging Findings in Cryptogenic Stroke Patients With and Without Patent Foramen Ovale

Background and Purpose—Patent foramen ovale (PFO) and cryptogenic stroke are commonly associated but some PFOs are incidental. Specific radiological findings associated with PFO may be more likely to indicate a PFO-related cause. We examined whether specific radiological findings are associated with PFO among subjects with cryptogenic stroke and known PFO status.

EURO INTERVENTION. The three year follow-up of the randomised “all-comers” trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS)

Aims: The current study reports clinical outcomes at three year follow-up of the LEADERS clinical trial which was the first all-comers trial comparing a new generation biodegradable polymer biolimus drug-eluting stent (BES) with the first generation permanent polymer sirolimus-eluting stent (SES).

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: The Stealth PK Study

Objectives: This prospective, open-label multicenter study was conducted to assess the pharmacokinetics of Biolimus A9 after elution from BioMatrix II coronary stents. Recent clinical trials have demonstrated the efficacy and safety of Biolimus A9 eluted from different stent platforms. To date, the pharmacokinetics of Biolimus A9 in patients following the deployment of BioMatrix II stents has not yet been studied

CIRCULATION. Real-Time Left Ventricular Pressure-Volume Loops During Percutaneous Mitral Valve Repair With the MitraClip System

Background—Percutaneous mitral valve repair with the MitraClip device has emerged as an alternative to surgery for treating severe mitral regurgitation. However, its effects on left ventricular loading conditions and contractility have not been investigated yet.

JACC. STEALTH I: 5-year Follow-up from a Prospective Randomized Study of Biolimus A9™-Eluting Stent with a Biodegradable Polymer Coating vs a Bare Metal Stent

JACC. LEADERS: 5-Year Follow-Up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Biodegradable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer- Final report of the LEADERS study

JACC. Three Year Outcomes Of Chronic Total Occlusion Treatment With Biolimus Eluting Biodegradable Polymer Stent Versus Sirolimus Eluting Permanent Polymer Stent In the LEADERS All-comers Trial

JACC. Impact of Renal Impairment on Clinical and Angiographic Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stents: a Pooled Analysis of SIRTAX, LEADERS, and RESOLUTE All-Comers Trials

EURO INTERVENTION. e-BioMatrix PMS Registry - A post market surveillance registry for the BioMatrix™ drug-eluting stent

Aims: The aim of the e-BioMatrix registry is to capture long-term clinical data of the BioMatrix stent system in relation to safety and effectiveness in a large population in routine clinical practice.

EURO INTERVENTION. Biolimus A9 drug eluting stents: comparative analyses of pharmacokinetics from three different stent platforms

Aims: Biolimus A9 is a proliferation signal inhibitors with unique properties that was specifically developed for coating on drug-eluting stents. Biolimus A9 is developed by the manufacturer Biosensors International and in the matrix with a biodegradable polylactic acid polymer is used in the second generation drug eluting stents. The aim of this study was to assess the pharmacokinetics of Biolimus A9 after elution from three different stent platforms.

EURO INTERVENTION. De novo coronary lesions treated with the novel polymer-free Biolimus-A9 coated stents: four- and twelve-month angiographic results from the prospective, randomised, multicentre BIOFREEDOM clinical trial

Aims: We report the results of the first-in-man evaluation of the BioFreedom (BF) Biolimus A9 (BA9) coated stent (Biosensors Int., Singapore), available in 2 different formulations: standard dose (SD: 15.6 μg/mm) and low dose (LD: 7.8 μg/mm).

EURO INTERVENTION. Long-term tissue coverage of a bioresorbable polylactide polymer-coated Biolimus-eluting stent: comparative sequential assessment with optical coherence tomography till complete resorption of the polymer

Aims: To assess the tissue coverage of a biolimus-eluting stent (BES) with bioresorbable polymer in abluminal coating at 24 months, when the polymer has been completely resorbed, as compared to a control sirolimus-eluting stent (SES) with durable polymer, using optical coherence tomography (OCT).

CIRCULATION. Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation

Background—The multicenter PROTECT AF study (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) was conducted to determine whether percutaneous left atrial appendage closure with a filter device (Watchman) was noninferior to warfarin for stroke prevention in atrial fibrillation.

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Intravascular ultrasound-guided systematic two-stent techniques for coronary bifurcation lesions and reduced late stent thrombosis

Background: The effects of intravascular ultrasound (IVUS)-guided complex approaches using drug-eluting stents (DES) for coronary bifurcation lesions on clinical outcomes has not yet been studied in detail.